CTSS and Alzheimer disease: In addition, the potential of cathepsins as biomarkers for early diagnosis and disease progression in AD warrants further evaluation, involving systematic studies of cathepsin expression and activity at different stages of the disease, as well as their correlations with AD symptoms and progression.